Abaloparatide is marketed as Tymlos (approved April 2017 for postmenopausal osteoporosis; December 2022 for male osteoporosis). In the ACTIVE trial, it reduced vertebral fractures by 86% and non-ve...
View full compound profile →Vendors stocking
1
across 1 country
Total listings
1
0 in stock
Price range
€69.00
Median price per mg
€23.00
Most common size
3mg
1 listing
Stock health
0%
0 vendors · 0 listings
No listings match the current filters. Try adjusting your filters above.
This compound is an approved pharmaceutical. Prices shown are from research-grade vendors and may differ from prescription pricing. Consult a healthcare professional before use.
Prices last updated: 15 May 2026
Data sourced from 1 vendor website across 1 country
